GenrAb

Executive Summary

GenrAb is a San Diego-based pre-clinical biotechnology company founded in 2018 that discovers and develops neuroprotective monoclonal antibody therapies derived from natural immune responses in patients with neurological diseases. Its proprietary Antibody Gene Signature (AGS) technology enables the identification of rare, naturally occurring antibodies that can protect neurons and potentially halt disease progression. The company is currently in the pre-clinical stage with no disclosed funding or valuation, and its innovative approach could address significant unmet needs in neurodegenerative disorders. However, the lack of disclosed financials and pipeline details indicates early-stage risk.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept studies40% success
• Q4 2026Series A financing round50% success
• Q1 2027IND-enabling studies initiation30% success